Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ORGANIZATION
ORGANIZATION
- JMA Exec Matsumoto Tipped to Replace Adachi as Chuikyo Rep
July 3, 2014
- “No Need to Step Down” as Chair of Biz Lobby, Govt Panel Member: Takeda CEO
July 2, 2014
- Yokokura Reelected as JMA President, 3 Incumbents Retain Veep Seats
July 2, 2014
- Research-Driven Pharmas Could Diverge into 2 Groups Based on Dependence on Off-Patent Drugs: FPMAJ Chair
July 1, 2014
- Min-Iren Urges Novartis to Return “Unfair Profits”
June 24, 2014
- JMA President Yokokura to Serve Second Term
June 20, 2014
- Japan Diabetes Group Announces Recommendations on Proper Use of SGLT-2 Inhibitors
June 17, 2014
- Daiichi Sankyo Pres. Nakayama Elected as New President of PMAT
June 17, 2014
- New Price Cut Rule Barring Generic Replacement of Long-Listed Products: FPMAJ
June 17, 2014
- US-Japan Business Council Airs Concerns over Annual NHI Price Revision
June 13, 2014
- Member Companies Conducted 682 Clinical Trials in Japan in 2013: PhRMA/EFPIA
June 11, 2014
- Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
- Santen President Officially Becomes New OPMA Head
May 29, 2014
- FPMAJ, JPMA Issue Joint Statement Opposing Once-Yearly NHI Price Revision
May 29, 2014
- JPWA Chief Highlights Progress in Single-Product, Single-Price Trading
May 27, 2014
- MTPC, MSD Return to JPMA’s BOD
May 26, 2014
- Yearly NHI Price Revision Not Consistent with Growth Strategy: JPMA Exec
May 23, 2014
- Astellas Chair Nogimori Sworn in as Head of FPMAJ
May 22, 2014
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- Market Share of Generic Drugs Based on New Calculation Method Rose to 44.9% in 3rd Quarter of FY2013: JGA
May 19, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…